Surgery combined with controlled-release doxorubicin silk films as a treatment strategy in an orthotopic neuroblastoma mouse model

British Journal of Cancer

Volumn 111, Issue 4, 2014, Pages 708-715

  Chiu, B ^a   Coburn, J ^b   Pilichowska, M ^c   Holcroft, C ^c   Seib, F P ^d   Charest, A ^c   Kaplan, D L ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Tufts University   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

animal model; chemotherapy; controlled release; neuroblastoma; surgery

Indexed keywords

DOXORUBICIN; SILK;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CONTROL; CANCER MODEL; CELL DEATH; CELL VIABILITY; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FILM; GROWTH RATE; HISTOLOGY; HUMAN; HUMAN CELL; LOADING DRUG DOSE; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

ADRENAL GLAND NEOPLASMS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DELAYED-ACTION PREPARATIONS; DOXORUBICIN; DRUG CARRIERS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEUROBLASTOMA; SILK; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84906089486     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.324     Document Type: Article

References (37)

1. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Stat Methodol 57: 289-300.
2. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Schold SC (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345: 1008-1012.
3. Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216.
4. Ceelen WP, Hesse U, de Hemptinne B, Pattyn P (2000) Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer. Br J Surg 87: 1006-1015.
5. Davis RK, Smith LF, Thurgood RF, Kereszti Z, Straight RC (1990) Intraoperative phototherapy (PDT) and surgical resection in a mouse neuroblastoma model. Lasers Surg Med 10: 275-279.
6. El-Kareh AW, Secomb TW (1997) Theoretical models for drug delivery to solid tumors. Crit Rev Biomed Eng 25: 503-571.
7. Fuchs D, Christofferson R, Stridsberg M, Lindhagen E, Azarbayjani F (2009) Regression of orthotopic neuroblastoma in mice by targeting the endothelial and tumor cell compartments. J Transl Med 7: 16.
8. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM (1997) The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 57: 3823-3829.
9. Hansford LM, McKee AE, Zhang L, George RE, Gerstle JT, Thorner PS, Smith KM, Look AT, Yeger H, Miller FD, Irwin MS, Thiele CJ, Kaplan DR (2007) Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. Cancer Res 67: 11234-11243.
10. Henriksson KC, Almgren MA, Thurlow R, Varki NM, Chang CL (2004) A fluorescent orthotopic mouse model for reliable measurement and genetic modulation of human neuroblastoma metastasis. Clin Exp Metastasis 21: 563-570.
11. Kang TH, Mao CP, Lee SY, Chen A, Lee JH, Kim TW, Alvarez RD, Roden RB, Pardoll D, Hung CF, Wu TC (2013) Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res 73: 2493-2504.
12. La Quaglia MP, Kushner BH, Heller G, Bonilla MA, Lindsley KL, Cheung NK (1994) Stage 4 neuroblastoma diagnosed at more than 1 year of age: gross total resection and clinical outcome. J Pediatr Surg 29: 1162-1165. discussion 1165-1166.
13. La Quaglia MP, Kushner BH, Su W, Heller G, Kramer K, Abramson S, Rosen N, Wolden S, Cheung NK (2004) The impact of gross total resection on local control and survival in high-risk neuroblastoma. J Pediatr Surg 39: 412-417.
14. Maris JM (2010) Recent advances in neuroblastoma. N Engl J Med 362: 2202-2211.
15. Maris JM, Hogarty MD, Bagatell R, Cohn SL (2007) Neuroblastoma. Lancet 369: 2106-2120.
16. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341: 1165-1173.
17. Mueller BM, Reisfeld RA (1991) Potential of the scid mouse as a host for human tumors. Cancer Metastasis Rev 10: 193-200.
18. Park JR, Eggert A, Caron H (2008) Neuroblastoma: biology, prognosis, and treatment. Pediatr Clin North Am 55: 97-120.
19. Pastorino F, Di Paolo D, Piccardi F, Nico B, Ribatti D, Daga A, Baio G, Neumaier CE, Brignole C, Loi M, Marimpietri D, Pagnan G, Cilli M, Lepekhin EA, Garde SV, Longhi R, Corti A, Allen TM, Wu JJ, Ponzoni M (2008) Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. Clin Cancer Res 14: 7320-7329.
20. Perez CA, Matthay KK, Atkinson JB, Seeger RC, Shimada H, Haase GM, Stram DO, Gerbing RB, Lukens JN (2000) Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a Children's Cancer Group study. J Clin Oncol 18: 18-26.
21. Pritchard E, Szybala C, Boison D, Kaplan DL (2010) Silk fibroin encapsulated powder reservoirs for sustained release of adenosine. J Control Release 144: 159-167.
22. Pritchard EM, Valentin T, Panilaitis B, Omenetto F, Kaplan DL (2013) Antibiotic-releasing silk biomaterials for infection prevention and treatment. Adv Funct Mater 23: 854-861.
23. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
24. Rockwood DN, Preda RC, Yucel T, Wang X, Lovett ML, Kaplan DL (2011) Materials fabrication from Bombyx mori silk fibroin. Nat Protoc 6: 1612-1631.
25. Rubino C, Adjadj E, Guerin S, Guibout C, Shamsaldin A, Dondon MG, Valteau-Couanet D, Hartmann O, Hawkins M, de Vathaire F (2003) Long-term risk of second malignant neoplasms after neuroblastoma in childhood: role of treatment. Int J Cancer 107: 791-796.
26. Seib FP, Jones GT, Rnjak-Kovacina J, Lin Y, Kaplan DL (2013a) pH-Dependent anticancer drug release from silk nanoparticles. Adv Healthc Mater 2: 1606-1611.
27. Seib FP, Kaplan DL (2012) Doxorubicin-loaded silk films: drug-silk interactions and in vivo performance in human orthotopic breast cancer. Biomaterials 33: 8442-8450.
28. Seib FP, Kaplan DL (2013) Silk for drug delivery applications: opportunities and challenges. Israel J Chem 53: 756-766.
29. Seib FP, Pritchard EM, Kaplan DL (2013b) Self-assembling doxorubicin silk hydrogels for the focal treatment of primary breast cancer. Adv Funct Mater 23: 58-65.
30. Shafford EA, Rogers DW, Pritchard J (1984) Advanced neuroblastoma: improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26. J Clin Oncol 2: 742-747.
31. Teitz T, Stanke JJ, Federico S, Bradley CL, Brennan R, Zhang J, Johnson MD, Sedlacik J, Inoue M, Zhang ZM, Frase S, Rehg JE, Hillenbrand CM, Finkelstein D, Calabrese C, Dyer MA, Lahti JM (2011) Preclinical models for neuroblastoma: establishing a baseline for treatment. PLoS One 6: e19133.
32. Tsioris K, Raja WK, Pritchard EM, Panilaitis B, Kaplan DL, Omenetto FG (2012) Fabrication of silk microneedles for controlled-release drug delivery. Adv Funct Mater 22: 330-335.
33. Tzoracoleftherakis EE, Spiliotis JD, Kyriakopoulou T, Kakkos SK (1999) Intra-arterial versus systemic chemotherapy for non-operable hepatocellular carcinoma. Hepatogastroenterol 46: 1122-1125.
34. Van der Meijden AP, Kurth KH, Oosterlinck W, Debruyne FM (1992) Intravesical therapy with adriamycin and 4-epirubicin for superficial bladder cancer: the experience of the EORTC GU Group. Cancer Chemother Pharmacol 30(Suppl): S95-S98.
35. Wang X, Wenk E, Matsumoto A, Meinel L, Li C, Kaplan DL (2007) Silk microspheres for encapsulation and controlled release. J Control Release 117: 360-370.
36. Westphal M, Ram Z, Riddle V, Hilt D, Bortey E. Executive Committee of the Gliadel Study Group (2006) Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 148: 269-275discussion 275.
37. Zhang J, Pritchard E, Hu X, Valentin T, Panilaitis B, Omenetto FG, Kaplan DL (2012) Stabilization of vaccines and antibiotics in silk and eliminating the cold chain. Proc Natl Acad Sci USA 109: 11981-11986.